Independent Trading Group

May 9, 2023

TORONTO, ON – TheNewswire - May 9, 2023 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE:AIAI) (Frankfurt:8TV) (OTC:AINMF) announces that it has engaged Independent Trading Group (ITG) Inc. ("ITG") to provide market-making services in accordance with the Canadian Securities Exchange ("CSE") policies. ITG will be responsible for trading shares of the Company on the CSE and other trading venues to help maintain a reasonable market and enhance the liquidity of the Company's common shares. Under the agreement, ITG will receive CAD$6,000 per month. The contract is on a month-to-month term and automatically renews unless terminated by either party with 30 days' notice. There are no performance factors in the contract, and ITG will not receive shares or options as compensation. At the time of the agreement, neither ITG nor its principals had an interest, directly or indirectly, in the securities of the Company. The appointment of ITG is subject to the approval of the CSE. "Engaging ITG as our market maker is an important step for NetraMark, as we seek to enhance the liquidity and trading of our common shares." said CEO, George Achilleos. Independent Trading Group Inc. is a Toronto-based IIROC dealer-member specializing in market making, liquidity provision, agency execution, ultra-low latency connectivity, and bespoke algorithmic trading solutions. Established in 1992, ITG has leveraged its proprietary technology to deliver high-quality liquidity provision and execution services to various public issuers and institutional investors. NetraMark is a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI / ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and / or efficacy of treatment. For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR). This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation including statements regarding the terms of ITG’s engagement and regulatory approval which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com including our Management’s Discussion and Analysis for the year ended September 30, 2022. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.